Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

08.08.23	Eli Lilly Boosts Outlook As Q2 Results Top Estimates; Stock Up 11% (RTTNews)
08.08.23	Eli Lilly Up Over 11% In Pre-market After Increased Q2 Profit, Outlook (RTTNews)
08.08.23	Eli Lilly Boosts FY23 Outlook - Update (RTTNews)
08.08.23	Eli Lilly And Co. Q2 Profit Increases, beats estimates (RTTNews)
08.08.23	Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements (PR Newswire)
04.08.23	Eli Lilly: LIBRETTO-431 Study Meets Primary Endpoint (RTTNews)
04.08.23	Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Adva... (PR Newswire)
27.07.23	Lilly's Diabetes Drug Tirzepatide Demonstrates Significant And Superior Weight Loss In Two Studies (RTTNews)
27.07.23	Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies (PR Newswire)
25.07.23	Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement (PR Newswire)
25.07.23	Lilly Extends Tender Offer To Acquire DICE (RTTNews)
25.07.23	Lilly Announces Extension of Tender Offer to Acquire DICE (PR Newswire)
18.07.23	Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline (RTTNews)
17.07.23	Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA (PR Newswire)
17.07.23	Sangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus Capsids (RTTNews)
14.07.23	Eli Lilly To Acquire Versanis Bio - Quick Facts (RTTNews)
14.07.23	Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases (PR Newswire)
11.07.23	Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC (PR Newswire)
06.07.23	New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PR Newswire)
29.06.23	Eli Lilly To Acquire Sigilon Therapeutics (RTTNews)
29.06.23	Lilly to Acquire Sigilon Therapeutics (PR Newswire)
27.06.23	Eli Lilly's Obesity Drug Retatrutide Leads To 24.2% Weight Loss In Phase 2 Trial (RTTNews)
27.06.23	Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity... (PR Newswire)
26.06.23	Lilly Declares Third-Quarter 2023 Dividend (PR Newswire)
24.06.23	Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes (PR Newswire)
24.06.23	Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we... (PR Newswire)
21.06.23	US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older (PR Newswire)
21.06.23	FDA Approves Boehringer Ingelheim' Jardiance And Synjardy To Treat Pediatric Type 2 Diabetes (RTTNews)
20.06.23	Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions (PR Newswire)
20.06.23	Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap" (PR Newswire)
20.06.23	Eli Lilly To Acquire DICE Therapeutics For $48/share All-cash Deal (RTTNews)
20.06.23	Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology (PR Newswire)
16.06.23	First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention (PR Newswire)
02.06.23	Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting (PR Newswire)
30.05.23	Lilly to Participate in Goldman Sachs Global Healthcare Conference (PR Newswire)
22.05.23	Lilly ESG Report Highlights Progress Towards Sustainability Goals (PR Newswire)
18.05.23	Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine (PR Newswire)
11.05.23	Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting (PR Newswire)
09.05.23	Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation (PR Newswire)
09.05.23	Eli Lilly Reports Interim Results From The Phase 2 Study Of Mirikizumab (RTTNews)
09.05.23	Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis (PR Newswire)
03.05.23	Eli Lilly: Donanemab Meets Primary Endpoint In Phase 3 Study Of Early Alzheimer's Disease (RTTNews)
01.05.23	Lilly Declares Second-Quarter 2023 Dividend (PR Newswire)
01.05.23	Lilly Says Lebrikizumab Improved 'face Or Hand Dermatitis' At 16 Weeks (RTTNews)
01.05.23	Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis (PR Newswire)
27.04.23	Lilly Q1 Profit Down, Misses View; Lifts FY23 Forecast; Stock Up In Pre Market (RTTNews)
27.04.23	Eli Lilly And Co. Q1 Profit Decreases, misses estimates (RTTNews)
27.04.23	Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum (PR Newswire)
27.04.23	Eli Lilly: Tirzepatide Achieves Up To 15.7% Weight Loss In Results From SURMOUNT-2 (RTTNews)
27.04.23	Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer

22:34

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone

17:56

Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an

16:06

Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa